Beyond Air, Inc. (XAIR) News

Beyond Air, Inc. (XAIR): $9.96

1.50 (+17.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter XAIR News Items

XAIR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XAIR News Highlights

  • XAIR's 30 day story count now stands at 5.
  • Over the past 19 days, the trend for XAIR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about XAIR are DRUG, LUNG and CE.

Latest XAIR News From Around the Web

Below are the latest news stories about Beyond Air Inc that investors may wish to consider to help them evaluate XAIR as an investment opportunity.

Beyond Air (NASDAQ:XAIR) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 22, 2022

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022

LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised $30 million for oncology affiliate Beyond Cancer™, Beyond Air maintained an 80% equity ownership; first in human trial initiation on track for first half of calendar year 2022 Expansion of leadership team with appointment of Dr. Andrew Colin to Chief Medical Officer tasked with leading the strategic

Yahoo | February 10, 2022

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive

Yahoo | February 8, 2022

Beyond Air® Announces Two Appointments to Beyond Cancer Board of Directors

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk joins with 30+ years of medical experience with oncology expertise in clinical trials, drug development, and regulatory strategy in both industry and academia GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR ), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

Benzinga | February 3, 2022

Beyond Air® Announces Two Appointments to Beyond Cancer™ Board of Directors

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk joins with 30+ years of medical experience with oncology expertise in clinical trials, drug development, and regulatory strategy in both industry and academia GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company

Yahoo | February 3, 2022

Beyond Air® Schedules Third Fiscal Quarter 2022 Financial Results Conference Call and Webcast

Call scheduled for Thursday, February 10th at 4:30 pm Eastern TimeGARDEN CITY, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumo

Yahoo | January 27, 2022

Head-To-Head Contrast: TELA Bio (NASDAQ:TELA) vs. Beyond Air (NASDAQ:XAIR)

TELA Bio (NASDAQ:TELA) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability. Profitability This table compares TELA Bio and Beyond Airs net margins, return on equity and []

Transcript Daily | December 18, 2021

Beyond Air CEO buys $341K in common stock

No summary available.

Seeking Alpha | December 14, 2021

Beyond Air Inc (XAIR) CEO and Chairman of the Board Steven A. Lisi Bought $341,200 of Shares

CEO and Chairman of the Board of Beyond Air Inc (30-Year Financial, Insider Trades) Steven A. Lisi (insider trades) bought 40,000 shares of XAIR on 12/10/2021 at an average price of $8.53 a share.

Yahoo | December 14, 2021

Insider Buying: Beyond Air, Inc. (NASDAQ:XAIR) CEO Acquires 40,000 Shares of Stock

Beyond Air, Inc. (NASDAQ:XAIR) CEO Steven A. Lisi acquired 40,000 shares of the business’s stock in a transaction on Friday, December 10th. The stock was acquired at an average cost of $8.53 per share, with a total value of $341,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through […]

Dakota Financial News | December 13, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7895 seconds.